Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,267 across all filing types
Latest filing 2019-10-30 Board/Management Inform…
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform that Ms. Revathy Ashok (DIN: 00057539), Non-Executive Independent ....
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in the chairmanship of the Stakeholders' Relationship Committee. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and informs about a director stepping down from a committee chairmanship position. There is no financial data, no report attached or referenced as being published, and no mention of voting results or other report types. This is a management or board-related announcement about committee membership changes, fitting the category of Board/Management Information (MANG). The document length is short and focused solely on this change, confirming it is not a full report or announcement of a report publication.
2019-10-30 English
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose advertisements given in Business Standard and Udayavani on October 25, ....
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled for November 11, 2019, to consider and approve the unaudited financial results for the quarter ended September 30, 2019. It is a newspaper advertisement pursuant to SEBI regulations informing about the upcoming Board Meeting. The document does not contain actual financial results or detailed financial data but is an announcement related to a corporate event. The length is short (3543 characters) and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice.
2019-10-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled for November 11, 2019, to consider and approve the unaudited financial results for the quarter ended September 30, 2019. It is a newspaper advertisement pursuant to SEBI regulations about the upcoming Board Meeting. The document does not contain any financial data or results itself, but rather announces the meeting where such results will be considered. The document length is 3646 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about a Board Meeting and financial results approval, not the financial report itself or a detailed management discussion.
2019-10-25 English
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2019 ,inter alia, to consider and approve the Unaudited Financial ....
Regulatory Filings Classification · 95% confidence The document is a letter dated October 24, 2019, addressed to stock exchanges notifying about a future Board of Directors meeting scheduled for November 11, 2019. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter ended September 30, 2019. The letter also mentions the closure of the trading window for insiders. The document is short (2081 characters) and serves as an announcement of an upcoming board meeting and financial results approval, not the financial results report itself. It does not contain any financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Interim Report or Board/Management Information (which would require actual changes in board or management).
2019-10-24 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter dated October 24, 2019, addressed to stock exchanges notifying about a forthcoming Board of Directors meeting scheduled for November 11, 2019. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter ended September 30, 2019. The letter also mentions the closure of the trading window for insiders. The document does not contain any financial data or results itself, but is an announcement of an upcoming board meeting and related procedural information. The document length is short (2081 characters) and it serves as a notification rather than a report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification to exchanges about board meetings and financial result approvals.
2019-10-24 English
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary ....
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the transfer of securities during a specified period. It is signed by a Practicing Company Secretary and certifies compliance with regulatory requirements related to share transfers. The document is not a financial report, earnings release, or management discussion, but rather a regulatory compliance certificate. It is also relatively short (3211 characters) and does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance documents and certifications that do not fit other specific categories.
2019-10-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.